Table 1.
Patient demographics. Patient demographic and clinical data were included for the 27 chronic carriers of the hepatitis B virus infections and six occult hepatitis B virus infections that could be amplified by nested PCR
| HBV infection n = 33 | Chronic n = 27 | Occult n = 6 |
|---|---|---|
| Age* | 35.8 years (21.2–58) | 35.4 years (26.7–42.2) |
| Race | ||
| African-American | 14 (51.9%) | 3 (50.0%) |
| Caucasian | 12 (44.4%) | 2 (33.3%) |
| Other | 1 (3.7%) | 1 (16.7%) |
| Gender | ||
| Male | 27 (100%) | 5 (83.3%) |
| Female | 0 | 1 (16.7%) |
| ALT*,† | 56.0 U/L | 27.0 U/L |
| n = 31 | (17–140) | (23–87) |
| HCV serostatus† | 0 | 1 (25%) |
| n = 21 | ||
| HIV† | ||
| Detectable | 21/23 (91%) | 5/5 (100%) |
| Viral load* | 6.0 × 104 copies/mL (7.2 × 102–2.0 × 105) | 1.7 × 105 copies/mL (1.0 × 104–3.7 × 105) |
| ART | ||
| On therapy | 6 (22.2%) | 1 (16.7%) |
| With HBV activity | 7‡ (100%) | 0 |
| CD4+ count*,† | 330.5 cells/mL (7–665) | 141.0 cells/mL (6–559) |
| HBV DNA* | 9.0 × 106 IU/mL (2.1 × 102–7.6 × 108) | 1.4 × 104 IU/mL (1.1 × 103–7.6 × 105) |
Local normal ALT levels were 5–46 U/L [25]; ALT levels are considered elevated when >92 U/L (two times the upper limit of normal). HCV serostatus was evaluated using anti-HCV ELISA. ART, antiretroviral therapy.
Median values are given with the range in parentheses.
Information was not available for all individuals (the number of patients with available information is listed under the heading); therefore, the median ALT and CD4+ count and percent detectable HCV and HIV are given for the individuals tested.
One additional individual is on HBV mono-therapy but not ART.